Late-night rocket launch in Florida: When to see from Vero Beach to Port St. Lucie to Fort Pierce
A late-night rocket launch from Florida is on the horizon.
SpaceX is set to launch a batch of Starlink satellites into low-Earth orbit on June 22 from Cape Canaveral.
Rockets here launch from NASA's Kennedy Space Center or nearby Cape Canaveral Space Force Station.
Weather permitting and depending on cloud cover, a rocket launch from Florida's Space Coast could be visible as far north as Jacksonville Beach and Daytona Beach to as far south as Vero Beach and West Palm Beach. When there's a launch window in the middle of the night or very early morning, there's an opportunity for unique photos — the rocket lights up the dark sky and the contrail after makes for a great photo.
Below is more information about the SpaceX rocket launch in Florida and suggestions on where to watch them from here.
Rocket launch tally: Here's a list of all 2025 missions from Cape Canaveral, Florida (psst, there's a lot)
For questions or comments, email FLORIDA TODAY Space Reporter Rick Neale at rneale@floridatoday.com or Space Reporter Brooke Edwards at bedwards@floridatoday.com. For more space news from the USA TODAY Network, visit floridatoday.com/space.
Tom Cruise and untitled SpaceX project: 'Mission: Impossible' star who lives in Florida may shoot a film in outer space
Mission: A SpaceX Falcon 9 rocket will launch a payload of Starlink broadband satellites into low-Earth orbit, a National Geospatial-Intelligence Agency navigational warning shows.
Launch window: 1:47 a.m. to 6:17 a.m. ET Sunday, June 22, 2025
Launch location: Launch complex 40 at Cape Canaveral Space Force Station in Cape Canaveral, Florida
Sonic booms: No
Trajectory: Northeast
Live coverage starts 90 minutes before liftoff at : You can watch live rocket launch coverage from USA TODAY Network's Space Team, which consists of FLORIDA TODAY space reporters Rick Neale and Brooke Edwards and visuals journalists Craig Bailey, Malcolm Denemark and Tim Shortt. Our Space Team will provide up-to-the-minute updates in a mobile-friendly live blog, complete with a countdown clock, at floridatoday.com/space, starting 90 minutes before liftoff. You can download the free FLORIDA TODAY app, which is available in the App Store or Google Play, or type into your browser.
Shown is the National Weather Service-Melbourne radar, which shows conditions in real-time for the Space Coast, Brevard County, Orlando and other parts of Florida. The current date and time show up on the bottom right of this radar embed; otherwise, you may need to clear your cache.
Sebastian Inlet State Park, 9700 S. State Road A1A, Melbourne Beach, Florida (cost to enter)
Wabasso Beach Park, 1808 Wabasso Beach Road, Wabasso, Florida
Ambersands Beach Park, 12566 N. SR A1A, Vero Beach, Florida (free parking)
South Beach Park, 1700 Ocean Drive, Vero Beach, Florida (free parking)
Merrill Barber Bridge in Vero Beach, Florida
Alma Lee Loy Bridge in Vero Beach, Florida
Fort Pierce Inlet State Park, 905 Shorewinds Drive, Fort Pierce, Florida
Blind Creek Beachside North and South, 5460 S. Ocean Drive, Fort Pierce, Florida
Blue Heron Beach, 2101 Blue Heron Blvd., Fort Pierce, Florida
Frederick Douglass Memorial Park, 3600 S. Ocean Drive, Fort Pierce, Florida
Dollman Park Beachside, 9200 S. Ocean Drive, Jensen Beach, Florida
Herman's Bay Beach, 7880 S. Ocean Drive, Jensen Beach, Florida
John Brooks Park Beachside, 3300 S. Ocean Drive, Fort Pierce, Florida
Middle Cove Beach, 4600 S. Ocean Drive, Fort Pierce, Florida
Normandy Beach in Jensen Beach, Florida
Pepper Park Beachside, 3302 N. SR A1A, Fort Pierce, Florida
Walton Rocks Beach, 6700 S. Ocean Drive, Jensen Beach, Florida (dog park)
Waveland Beach, 10350 S. Ocean Drive, Jensen Beach, Florida
State Road A1A causeway in Stuart, Florida
House of Refuge and beach, 301 S.E. MacArthur Blvd., Stuart, Florida
This article originally appeared on Treasure Coast Newspapers: SpaceX nighttime rocket launch in Florida: What time is liftoff?
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
26 minutes ago
- New York Post
Dog's ashes among dozens to rocket into orbit this weekend
Bone voyage! A beloved dog named Franz will take his final leap this weekend — into Earth's orbit. The yellow labrador's ashes will be on board the inaugural Perseverance Flight from Texas-based Celestis Inc., which is scheduled to launch around 5:30 p.m. Sunday from Vandenberg Space Force Base in Santa Barbara, CA. 4 Franz was like a sibling to Elizabeth Moore before he died at age 13 in October 2020. Celestis, Inc Carrying a total of 166 titanium and aluminum capsules, each about a quarter to a half-inch in size and filled with DNA or cremated remains, the 23-foot-tall SpaceX Falcon 9 rocket will take two trips around Earth's low orbit at a mind-boggling 17,000 mph. The space flight will last about three hours before the rocket — still carrying its priceless payload — re-enters the atmosphere and lands in the Pacific Ocean somewhere between Alaska and Hawaii, according to Celestis CEO and co-founder Charles Chafer. A recovery ship, which was already out at sea Friday in anticipation of the launch, 'will track the incoming rocket, hopefully get a visual on it, and then go pick it up out of the ocean,' Chafer explained. 4 The Texas-based company Celestis Inc.'s inaugural Perseverance Flight will take two trips around Earth's Lower Orbit after blastoff on Sunday. The capsules will first be transported to Germany, then, within two months, distributed back to the families, who each paid a whopping $3,500 to send their loved one to the stars. While the price to send Franz on the voyage was 'a lot more' than the pooch itself, his owner, Harvin Moore, said with a laugh, it was only fitting for the 'space-fanatic' Moore family to send the pup beyond the stratosphere. 'He was the best dog, just so soft and nice and loved hugs,' recalled Moore, 60, who lives in Dripping Springs, Texas, just outside Austin. 4 The Moore family can't wait to watch their beloved pooch go galactic. Celestis, Inc Franz, who was 13 when he died in October 2020, was more like a sibling than a pet to Moore's now 26-year-old daughter, Elizabeth, and son, Quinn, 21, he said. Now, the family can't wait to watch the good boy go galactic. 'The emotional power of being with a group of people who are celebrating the life of a loved one in this way … it's amazing. It's nothing we'll ever forget,' said Moore. 'It's just pure joy.' 4 The Perseverance Flight will carry a total of 166 titanium and aluminum capsules, ranging in size from a quarter to a half-inch, filled with DNA or cremated remains. Celestis, Inc 'Many people whose ashes and DNA are flying are people that always wanted to go to space in their lifetime but were never able to do that. It also helps families move from feelings of grief to joy,' Chafer said. The cremated remains of Wesley Dreyer — an aerospace engineer who helped investigate the cause of the Space Shuttle Challenger's shocking explosion after takeoff on Jan. 28, 1986 — will also be on board the Perseverance Flight, as well as DNA from a living, 3-year-old German boy.
Yahoo
an hour ago
- Yahoo
DARPA smashes wireless power record, beaming energy more than 5 miles away — and uses it to make popcorn
When you buy through links on our articles, Future and its syndication partners may earn a commission. The U.S. military has set a new record for wireless power transmission, beaming a laser carrying more than 800 watts of power across a distance of 5.3 miles (8.6 kilometers). The test, performed by the U.S. military's Defense Advanced Research Projects Agency (DARPA) as part of its Persistent Optical Wireless Energy Relay (POWER) program, is a key step toward unlocking the near-instant beaming of power. It also smashes previous records set by the POWER program, which previously beamed 230 watts across 1 mile (1.7 km) for 25 seconds, and a smaller, undisclosed amount of power as far as 2.3 miles (3.7 km). "It is beyond a doubt that we absolutely obliterated all previously reported optical power beaming demonstrations for power and distance," Paul Jaffe, the POWER program manager, said in a statement. The concept of wireless power transmission (WPT) has been a popular goal since the days of Nikola Tesla, who in 1901 began constructing the Wardenclyffe Tower on Long Island, New York — a 187-foot (57 meters) structure intended to be the first node in a "World Wireless System" that would beam power around the globe. Yet technical challenges meant that funding for the project, initially provided by the financier J.P. Morgan, dried up, leaving Tesla's vision unrealized. Related: NASA's 1st successful 2-way laser experiment is a giant leap for moon and Mars communications Nonetheless, interest in the concept has recently increased, both for military applications and space-based solar power, a nascent technology that would collect and transmit energy from sunlight in space, where it is 10 times more intense than at Earth's surface. Energy is essential for military operations, and getting that energy to the battlefields and disaster areas where it's needed is slow, risky, and resource intensive, often using up a lot of fuel, DARPA representatives wrote in the statement. RELATED STORIES —World's most powerful X-ray laser set for massive upgrade that will help us better understand the atomic world —DARPA's military-grade 'quantum laser' will use entangled photons to outshine conventional laser beams—Scientists uncover the secret to building Star Wars-style laser weapons — but don't worry, we won't have a Death Star anytime soon "These tests, referred to as PRAD (POWER Receiver Array Demo), mark an important step toward the POWER program's long-term goal of being able to instantly beam power from a location where it can be easily generated to wherever it's needed," the agency added. In the latest experiment, conducted at the U.S. Army's White Sands Missile Range in New Mexico, the power was beamed over the 5.3-mile distance in a 30-second pulse. The laser beam arrived at the receiver before passing through a small aperture, bouncing off a parabolic mirror onto solar cells within. The pulse was transmitted with an approximate 20% efficiency, and some of the power it transmitted was used to make popcorn. The researchers have bigger ambitions for the system's use in the field, however, suggesting that it could be used to power unmanned aerial vehicles (UAVs). They will now move on to testing power beaming both across multiple connected relays and vertically, where the atmosphere is thinner and transmission more efficient.
Yahoo
an hour ago
- Yahoo
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2 Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical data On track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all patients who have received at least one treatment of [212Pb]VMT-α-NET and anti-tumor activities in patients dosed to date who have had the opportunity to receive at least one scan after their full treatment SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that alignment was reached with the U.S. Food and Drug Administration (FDA) to open the third dosing cohort (Cohort 3) of its ongoing Phase 1/2a clinical trial for [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT). "We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial," commented Markus Puhlmann, Chief Medical Officer of Perspective. "We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile. Meanwhile, we remain committed to engaging with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of our proprietary RPTs." Patients in Cohort 3 will receive up to four fixed administered doses of [212Pb]VMT-α-NET at 6 mCi every eight weeks if they weigh more than 60kg (133lb), or 100μCi/kg of body weight if they weigh less than or equal to 60kg. Observations of dose limiting toxicities (DLTs) in up to eight patients within 42 days of the first treatment cycle will be used to assess whether this cohort of patients have received maximum tolerated dose (MTD) or maximum feasible dose (MFD). Once a safety monitoring committee (SMC) has reviewed the data from these initial patients, it may recommend exploring alternative dosing and/or recruit more patients into Cohort 3. Perspective is notifying sites that Cohort 3 is now open for recruitment. Patients currently being evaluated for entry into the study will enroll into Cohort 3 if they qualify. Pending feedback from sites on operationalizing enrollment into Cohort 3, an update on pace of recruitment will be provided in due course. About [212Pb]VMT-α-NETPerspective designed [212Pb]VMT-α-NET to target and deliver 212Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study ( identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol. About Perspective Therapeutics, Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations. For more information, please visit the Company's website at Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's belief that it is on track to submit further clinical updates to scientific congresses in 2H 2025 and the planned content of such updates; the Company's ability to explore a higher dose level of VMT-α-NET; the Company's commitment to engage with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of its proprietary RPTs; the Company's expectation that patients currently being evaluated for entry into its VMT-α-NET study will enroll into Cohort 3 if they qualify; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Media and Investor Relations Contacts: Perspective Therapeutics IR:Annie J. Cheng, CFAir@ Russo Partners, LLCNic JohnsonPerspectiveIR@
